Form 4: Exact Sciences CEO Kevin Conroy Reports Stock Transactions
SEC Form 4 Filing
CEO Kevin Conroy reports transactions involving Exact Sciences Corp. common stock and restricted stock units.
Summary
- On February 28, 2025, Kevin Conroy, the President and CEO of Exact Sciences Corp., engaged in transactions involving the company's stock.
- These transactions included the vesting of restricted stock units and the subsequent acquisition of common stock.
- Shares were also withheld by Exact Sciences for tax purposes related to the vesting of these units.
- Conroy's direct holdings of common stock following these transactions amount to 1,136,546 shares.
- He also indirectly holds shares through a 401(k) plan and several Grantor Retained Annuity Trusts.
- Additionally, Conroy holds vested and unvested options and restricted stock units representing the right to acquire 730,301 additional shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing, reflecting standard executive stock transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the healthcare industry.
Comparison to Industry Standards
- Executive stock transactions are a normal part of corporate governance and are regularly disclosed by executives at comparable companies such as Guardant Health, Inc. and Illumina, Inc.
- The vesting schedules and equity compensation structures are also typical for executive compensation packages in the biotech industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and stock ownership adjustments.
Key Dates
| Date | Description |
|---|---|
| 02/24/2023 | Date of restricted stock unit award that partially vested on February 28, 2025. |
| 02/26/2024 | Date of restricted stock unit award that partially vested on February 28, 2025. |
| 02/28/2025 | Date of transactions involving common stock and restricted stock units. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.